PHASE II STUDY OF ERLOTINIB AS A FIRST-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER PATIENTS ACCORDING TO THEIR CLINICAL PREDICTORS

被引：0
作者：
Lee, D. H. [1 ]
Kim, H. T. [2 ]
Kim, S. [1 ]
Suh, C. [1 ]
Lee, J. [1 ]
机构：
[1] Asan Med Ctr, Dept Internal Med, Div Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Res Inst & Hosp, Ctr Lung Canc, Goyang, South Korea
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
[31]   Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer [J].
Shen, Yan-Wei ;
Zhang, Xiao-Man ;
Li, Shu-Ting ;
Lv, Meng ;
Yang, Jiao ;
Wang, Fan ;
Chen, Zhe-Ling ;
Wang, Bi-Yuan ;
Li, Pan ;
Chen, Ling ;
Yang, Jin .
ONCOTARGETS AND THERAPY, 2016, 9 :929-935
[32]   Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC) [J].
M. Faehling ;
J. Achenbach ;
P. Staib ;
U. Steffen ;
H. W. Tessen ;
V. E. Gaillard ;
W. Brugger .
Journal of Cancer Research and Clinical Oncology, 2018, 144 :1375-1383
[33]   Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients [J].
Grigorescu, A. C. ;
Bala, C. .
JOURNAL OF BUON, 2013, 18 (01) :188-194
[34]   Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC) [J].
Faehling, M. ;
Achenbach, J. ;
Staib, P. ;
Steffen, U. ;
Tessen, H. W. ;
Brugger, W. .
ANNALS OF ONCOLOGY, 2016, 27
[35]   Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC) [J].
Faehling, M. ;
Achenbach, J. ;
Staib, P. ;
Steffen, U. ;
Tessen, H. W. ;
Gaillard, V. E. ;
Brugger, W. .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (07) :1375-1383
[36]   Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer [J].
Butts, Charles A. ;
Bodkin, David ;
Middleman, Edward L. ;
Englund, Craig W. ;
Ellison, David ;
Alam, Yasmin ;
Kreisman, Harvey ;
Graze, Peter ;
Maher, James ;
Ross, Helen J. ;
Ellis, Peter M. ;
McNulty, William ;
Kaplan, Edward ;
Pautret, Virginie ;
Weber, Martin R. ;
Shepherd, Frances A. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (36) :5777-5784
[37]   A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer [J].
Schuette, Wolfgang H. W. ;
Groeschel, Andreas ;
Sebastian, Martin ;
Andreas, Stefan ;
Mueller, Thomas ;
Schneller, Folker ;
Guetz, Sylvia ;
Eschbach, Corinna ;
Bohnet, Sabine ;
Leschinger, Monika I. ;
Reck, Martin .
CLINICAL LUNG CANCER, 2013, 14 (03) :215-223
[38]   A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer (vol 29, pg 3567, 2011) [J].
Hirsch, Fred R. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (29) :3948-3948
[39]   Integrative transcriptome analysis in patients in a phase II clinical trial of first-line erlotinib for clinically selected patients with advanced non-small cell lung cancer [J].
Laskin, Janessa J. ;
Pugh, Trevor J. ;
Jackson, Cathy ;
Barclay, Lorena ;
Morin, Ryan ;
Ionescu, Diana ;
Melosky, Barbara ;
Cheryl, Ho ;
Sun, Sophie ;
Murray, Nevin R. ;
Marra, Marco A. .
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) :S328-S329
[40]   First-line treatment for advanced non-small-cell lung cancer [J].
Laskin, Janessa J. ;
Sandler, Alan B. .
ONCOLOGY-NEW YORK, 2005, 19 (13) :1671-1676
12345